Skip to main content
Premium Trial:

Request an Annual Quote

Discovery Life Sciences SpecimenSeq

Discovery Life Sciences has launched SpecimenSeq, a collection of high-quality, fully consented biospecimens to help researchers identify, develop, and validate new biomarker signatures for precision medicine applications.

SpecimenSeq is composed of matched biospecimen sets including FFPE, double-spun plasma, and buffy coat formats from treatment-naive cancer patients. The biospecimens are fully annotated with clinical data and the FFPE biospecimens specifically include clinically relevant genomic variants from 64 genes. Genomic data for SpecimenSeq are produced using the custom HAD QGEN MultiModal Panel-based DNA and RNA analysis service available exclusively through Discovery's sequencing and bioinformatics laboratory, HudsonAlpha Discovery. This panel service uses Qiagen's QIAseq MultiModal targeted DNA and RNA sequencing chemistry and analysis platform that is also available as a standalone service through HudsonAlpha Discovery with variant allele frequency detection at less than 5 percent.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.